Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2007

View Archived Issues

Vinorelbine-cisplatin confirmed superior in stage II-IIIA NSCLC / News in Context

Eisai: Q3 report

Recent patents report new therapeutic agents for metabolic disorders

Recent Nissan Chemical patents describe new treatment options for thrombocytopenia

Axcan updates Q1 developments

ZymoGenetics' rhThrombin BLA accepted for review

SGX reviews oncology pipeline

Ark Therapeutics discusses phase III Vitor study with regulatory agencies

Valeant acquires rights to nabilone in the U.K. and Europe

KeyNeurotek and Max-Planck sign licensing agreement

Merck begins registrations of Atripla in developing countries

Inspire to commercialize AzaSite in U.S. and Canada

Gestiva reduces cervical shortening

Canarypox HIV vaccine responses in phase II not sufficient for phase III investigation

Pipex Pharmaceuticals' Coprexa awarded NIH grant for Alzheimer's disease

Post hoc subgroup analysis for Chrysalin in fracture repair

Safety, absorption of TMC-120 assessed in women with and without HIV

Traditional Chinese preparation to enter the clinic for the treatment of allergic asthma

New agents for treating neurological disorders disclosed in recent patents

Recent patents disclose novel treatments for diabetes

Cadherin-11: a potential target against rheumatoid arthritis

Cognitive and mood improvement after guarana therapy reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...